Abstract
Overview
Introduction
The PD market is set to continue to grow over the next 7 years, reaching over
$2.37 billion in 2013, a 39% increase from 2006 levels. Combinations,
reformulations, and indication expansions will drive the majority of this
growth, with key brands expected to be Novartis/Orion' s Stalevo,
GlaxoSmithKline' s (GSK' s) Requip Modutab, and UCB-Schwarz' s Neupro.
Scope
- Analysis of patient potential, unmet needs and clinical trial design in PD
- Overview of key marketed brands, late- and early-stage pipeline drugs, and
cell/gene therapies.
- Indication- and country-specific sales volume and value forecasts to 2016
of marketed brands, generics, and key late-stage pipeline drugs.
- Identification of future market events that are expected to affect PD drug
revenues.
Highlights
GSK' s Requip Modutab will become the market leading PD brand in 2011. It will
be intuitive for prescribers to believe that sustained activation of dopamine
receptors with Requip Modutab could have a significant clinical benefit over
pulsed agonism with standard drugs.
New pipeline drugs will need to be innovative to compete in an increasingly
crowded market. While this is evident in Eisai' s E2007, it is lacking in
Merck-Serono/Newron' s safinamide.
Early studies with cell/gene therapies show great promise for significantly
slowing the progression of the disease. However, these alternative approaches
will not significantly impact the sales of pharmaceuticals over the forecast
period 20072016.
Reasons to Purchase
- Benchmark key late-stage PD compounds against current market leading
brands.
- Assess country-specific (US, Japan, France, Germany, Italy, Spain and the
UK) sales forecasts of key late-stage pipeline drugs and marketed brands.
- Understand unmet needs and opportunities in the PD market based on key
opinion leader comments.
| 
View Cart
